Share Price and Basic Stock Data
Last Updated: December 30, 2025, 8:53 pm
| PEG Ratio | 11.90 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Genomic Valley Biotech Ltd operates within the seeds, tissue culture, and biotechnology sector. The company’s reported sales have shown volatility, with revenue standing at ₹2.72 Cr for the fiscal year ending March 2023, a significant increase from ₹0.07 Cr in March 2022. However, subsequent quarterly performances have exhibited inconsistent results, with sales recorded at ₹0.07 Cr in September 2023 and ₹0.04 Cr in December 2023. Despite these fluctuations, the company has a trailing twelve-month (TTM) revenue of ₹0.66 Cr, indicating a challenging revenue environment. The cash conversion cycle (CCC) is notably high at 1,429.58 days, reflecting potential inefficiencies in working capital management. This prolonged CCC might hinder operational agility, making it critical for the company to streamline its sales and inventory processes to enhance its revenue trajectory.
Profitability and Efficiency Metrics
Profitability metrics for Genomic Valley Biotech Ltd reveal a mixed performance. The operating profit margin (OPM) was reported at 0.00% for the most recent annual period, indicating challenges in converting sales into profits. However, the OPM showed a peak of 93.00% in March 2023, followed by a decline to 28.57% in September 2023. The net profit for the fiscal year ending March 2023 stood at ₹0.65 Cr, translating to an earnings per share (EPS) of ₹2.13. This marks a recovery from a net loss of ₹0.01 Cr in March 2022. Return on equity (ROE) is reported at 9.69%, and return on capital employed (ROCE) at 11.8%, supporting the company’s ability to generate returns relative to shareholder equity and total capital employed. However, the interest coverage ratio (ICR) of 0.00x indicates that the company is not generating sufficient earnings to cover interest obligations, posing a significant risk to financial stability.
Balance Sheet Strength and Financial Ratios
Genomic Valley Biotech Ltd maintains a balance sheet with no reported borrowings, a significant strength that suggests a low-risk financial position. The total assets stood at ₹4.36 Cr, with equity capital of ₹3.05 Cr and reserves amounting to ₹0.84 Cr as of March 2025. The company’s current ratio is reported at 5.73x, indicating strong liquidity and the ability to cover short-term liabilities. However, the price-to-book value (P/BV) ratio of 4.59x suggests that the stock is trading at a premium relative to its book value, which may raise concerns among value-oriented investors. The asset turnover ratio of 0.19% indicates inefficiencies in utilizing assets to generate sales. Overall, while the absence of debt is a strength, the company must address operational inefficiencies to enhance its financial health.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Genomic Valley Biotech Ltd reveals a gradual decrease in promoter holdings from 67.85% in December 2022 to 46.72% as of September 2025, reflecting a potential dilution of control. Conversely, public shareholding has increased from 32.15% to 53.29% during the same period, indicating growing interest from retail investors. The total number of shareholders has also risen significantly, from 377 in December 2022 to 2,459 in September 2025, suggesting increased investor confidence in the firm. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could be a concern, as it may limit access to larger pools of capital and strategic insights. The shift in shareholding dynamics could impact the company’s governance and future strategic decisions, making it crucial for management to engage effectively with its expanding shareholder base.
Outlook, Risks, and Final Insight
Looking ahead, Genomic Valley Biotech Ltd faces both opportunities and risks. The company’s potential to improve revenue generation through operational efficiencies is a key strength, particularly in the context of its strong liquidity position. However, the high cash conversion cycle and lack of consistent profitability pose significant risks that could hinder growth. The reliance on promoter support amidst declining ownership may also create governance challenges. To enhance shareholder value, the company must focus on improving operational performance, reducing the cash conversion cycle, and potentially attracting institutional investment to stabilize its capital structure. The outlook hinges on management’s ability to navigate these challenges effectively while capitalizing on its strengths in the biotechnology sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Genomic Valley Biotech Ltd | 7.55 Cr. | 24.7 | 94.0/21.0 | 75.5 | 12.8 | 0.00 % | 11.8 % | 9.69 % | 10.0 |
| Genesis IBRC India Ltd | 111 Cr. | 85.7 | 185/17.5 | 6.42 | 0.00 % | 51.6 % | 51.6 % | 10.0 | |
| Shreeoswal Seeds & Chemicals Ltd | 164 Cr. | 18.0 | 20.3/10.7 | 16.4 | 5.23 | 0.00 % | 9.88 % | 8.41 % | 2.00 |
| Nath Bio-Genes (India) Ltd | 289 Cr. | 152 | 239/138 | 6.13 | 362 | 1.31 % | 7.35 % | 6.77 % | 10.0 |
| Continental Seeds and Chemicals Ltd | 30.5 Cr. | 22.2 | 41.6/19.3 | 39.6 | 22.5 | 0.00 % | 4.24 % | 2.87 % | 10.0 |
| Industry Average | 188.00 Cr | 60.52 | 34.41 | 81.79 | 0.26% | 16.97% | 15.87% | 8.40 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.02 | 0.67 | 1.00 | 0.06 | 0.07 | 0.04 | 0.00 | 0.16 | 0.21 | 0.22 | 0.26 | 0.09 | 0.09 |
| Expenses | 0.05 | 0.63 | 0.07 | 0.03 | 0.05 | 0.02 | 0.04 | 0.03 | 0.07 | 0.06 | 0.26 | 0.06 | 0.09 |
| Operating Profit | -0.03 | 0.04 | 0.93 | 0.03 | 0.02 | 0.02 | -0.04 | 0.13 | 0.14 | 0.16 | 0.00 | 0.03 | 0.00 |
| OPM % | -150.00% | 5.97% | 93.00% | 50.00% | 28.57% | 50.00% | 81.25% | 66.67% | 72.73% | 0.00% | 33.33% | 0.00% | |
| Other Income | 0.10 | -0.89 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.06 | -0.85 | 0.98 | 0.03 | 0.02 | 0.02 | -0.04 | 0.13 | 0.15 | 0.16 | 0.00 | 0.03 | 0.00 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | 0.06 | -0.85 | 0.98 | 0.03 | 0.02 | 0.02 | -0.04 | 0.13 | 0.15 | 0.16 | -0.08 | 0.02 | 0.00 |
| EPS in Rs | 0.20 | -2.78 | 3.21 | 0.10 | 0.07 | 0.07 | -0.13 | 0.43 | 0.49 | 0.52 | -0.26 | 0.07 | 0.00 |
Last Updated: December 26, 2025, 7:46 pm
Below is a detailed analysis of the quarterly data for Genomic Valley Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.09 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.09 Cr..
- For Expenses, as of Sep 2025, the value is 0.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.06 Cr. (Jun 2025) to 0.09 Cr., marking an increase of 0.03 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.03 Cr. (Jun 2025) to 0.00 Cr., marking a decrease of 0.03 Cr..
- For OPM %, as of Sep 2025, the value is 0.00%. The value appears to be declining and may need further review. It has decreased from 33.33% (Jun 2025) to 0.00%, marking a decrease of 33.33%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.03 Cr. (Jun 2025) to 0.00 Cr., marking a decrease of 0.03 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.02 Cr. (Jun 2025) to 0.00 Cr., marking a decrease of 0.02 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.00. The value appears to be declining and may need further review. It has decreased from 0.07 (Jun 2025) to 0.00, marking a decrease of 0.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.09 | 0.03 | 0.11 | 0.44 | 0.59 | 0.99 | 0.85 | 0.21 | 0.07 | 2.72 | 0.17 | 0.84 | 0.66 |
| Expenses | 0.08 | 0.07 | 0.54 | 0.48 | 0.49 | 0.57 | 0.30 | 0.34 | 0.45 | 1.84 | 0.15 | 0.40 | 0.47 |
| Operating Profit | 0.01 | -0.04 | -0.43 | -0.04 | 0.10 | 0.42 | 0.55 | -0.13 | -0.38 | 0.88 | 0.02 | 0.44 | 0.19 |
| OPM % | 11.11% | -133.33% | -390.91% | -9.09% | 16.95% | 42.42% | 64.71% | -61.90% | -542.86% | 32.35% | 11.76% | 52.38% | 28.79% |
| Other Income | 0.01 | 0.07 | 0.16 | 0.01 | 0.03 | 0.01 | 0.01 | 0.00 | 0.50 | -0.22 | 0.00 | 0.00 | 0.00 |
| Interest | 0.01 | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | 0.18 | 0.18 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.01 | 0.05 | 0.04 | 0.08 | 0.19 | 0.18 | 0.19 | 0.08 | 0.01 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.01 | -0.01 | -0.34 | -0.07 | 0.05 | 0.24 | 0.20 | -0.50 | 0.00 | 0.65 | 0.02 | 0.44 | 0.19 |
| Tax % | 0.00% | 0.00% | -2.94% | 0.00% | 40.00% | 0.00% | -40.00% | 12.00% | 0.00% | 0.00% | 20.45% | ||
| Net Profit | 0.00 | -0.01 | -0.33 | -0.07 | 0.03 | 0.23 | 0.29 | -0.56 | -0.01 | 0.65 | 0.02 | 0.36 | 0.10 |
| EPS in Rs | 0.00 | -0.03 | -1.08 | -0.23 | 0.10 | 0.75 | 0.95 | -1.83 | -0.03 | 2.13 | 0.07 | 1.18 | 0.33 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -3200.00% | 78.79% | 142.86% | 666.67% | 26.09% | -293.10% | 98.21% | 6600.00% | -96.92% | 1700.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 3278.79% | 64.07% | 523.81% | -640.58% | -319.19% | 391.32% | 6501.79% | -6696.92% | 1796.92% |
Genomic Valley Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 40% |
| 5 Years: | 0% |
| 3 Years: | 129% |
| TTM: | 189% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 44% |
| 5 Years: | 4% |
| 3 Years: | 42% |
| TTM: | 92% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | % |
| 1 Year: | -42% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 2% |
| 3 Years: | 12% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: December 10, 2025, 4:23 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 |
| Reserves | 1.85 | 1.84 | 1.51 | 1.44 | 1.47 | 1.71 | 1.99 | 1.43 | -0.18 | 0.47 | 0.49 | 0.84 | 0.87 |
| Borrowings | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 1.48 | 1.48 | 1.55 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Other Liabilities | 0.61 | 0.80 | 0.73 | 0.78 | 1.41 | 0.94 | 1.49 | 1.59 | 0.92 | 0.90 | 0.79 | 0.47 | 0.41 |
| Total Liabilities | 6.26 | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 | 4.33 |
| Fixed Assets | 3.02 | 3.15 | 3.18 | 3.63 | 4.12 | 4.31 | 4.47 | 5.86 | 1.75 | -0.00 | -0.00 | 0.01 | 0.01 |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | 0.38 | 0.49 | 0.49 | 0.49 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | -0.00 | 0.55 | 0.11 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.02 | -0.00 | -0.00 |
| Other Assets | 3.24 | 2.74 | 2.75 | 2.39 | 2.18 | 2.38 | 3.05 | 1.27 | 2.04 | 4.42 | 4.31 | 4.35 | 4.32 |
| Total Assets | 6.26 | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 | 4.33 |
Below is a detailed analysis of the balance sheet data for Genomic Valley Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 3.05 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.05 Cr..
- For Reserves, as of Sep 2025, the value is 0.87 Cr.. The value appears strong and on an upward trend. It has increased from 0.84 Cr. (Mar 2025) to 0.87 Cr., marking an increase of 0.03 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.41 Cr.. The value appears to be improving (decreasing). It has decreased from 0.47 Cr. (Mar 2025) to 0.41 Cr., marking a decrease of 0.06 Cr..
- For Total Liabilities, as of Sep 2025, the value is 4.33 Cr.. The value appears to be improving (decreasing). It has decreased from 4.36 Cr. (Mar 2025) to 4.33 Cr., marking a decrease of 0.03 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 4.32 Cr.. The value appears to be declining and may need further review. It has decreased from 4.35 Cr. (Mar 2025) to 4.32 Cr., marking a decrease of 0.03 Cr..
- For Total Assets, as of Sep 2025, the value is 4.33 Cr.. The value appears to be declining and may need further review. It has decreased from 4.36 Cr. (Mar 2025) to 4.33 Cr., marking a decrease of 0.03 Cr..
Notably, the Reserves (0.87 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.74 | -0.79 | -1.18 | -0.79 | -0.65 | -1.06 | -0.93 | -1.68 | -0.38 | 0.88 | 0.02 | 0.44 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 960.30 |
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 486.67 | ||||||
| Days Payable | 17.38 | |||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 1,429.58 |
| Working Capital Days | 7,746.11 | -8,881.67 | -1,659.09 | -514.32 | -804.24 | 55.30 | -176.06 | -1,251.43 | 4,849.29 | 221.42 | 4,530.29 | 916.85 |
| ROCE % | 0.41% | 0.35% | -5.84% | -0.57% | 0.57% | 4.17% | 5.96% | -5.10% | -8.54% | 28.48% | 0.57% | 11.83% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.17 | 0.05 | 2.12 | -0.03 | -1.83 |
| Diluted EPS (Rs.) | 1.17 | 0.05 | 2.12 | -0.03 | -1.83 |
| Cash EPS (Rs.) | 1.17 | 0.05 | 2.15 | 0.24 | -1.21 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 12.76 | 11.60 | 11.55 | 9.42 | 14.69 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 12.76 | 11.60 | 11.55 | 9.42 | 14.69 |
| Revenue From Operations / Share (Rs.) | 2.76 | 0.54 | 8.91 | 0.23 | 0.68 |
| PBDIT / Share (Rs.) | 1.45 | 0.05 | 3.02 | -0.96 | -0.44 |
| PBIT / Share (Rs.) | 1.45 | 0.04 | 2.99 | -1.24 | -1.06 |
| PBT / Share (Rs.) | 1.45 | 0.04 | 2.12 | -1.38 | -1.64 |
| Net Profit / Share (Rs.) | 1.17 | 0.04 | 2.12 | -0.03 | -1.83 |
| PBDIT Margin (%) | 52.60 | 9.83 | 33.83 | -416.43 | -64.94 |
| PBIT Margin (%) | 52.30 | 9.17 | 33.54 | -535.97 | -155.88 |
| PBT Margin (%) | 52.30 | 9.17 | 23.83 | -596.37 | -241.16 |
| Net Profit Margin (%) | 42.19 | 9.19 | 23.81 | -13.23 | -268.67 |
| Return on Networth / Equity (%) | 9.13 | 0.42 | 18.38 | -0.32 | -12.45 |
| Return on Capital Employeed (%) | 11.32 | 0.42 | 25.89 | -10.55 | -4.80 |
| Return On Assets (%) | 8.17 | 0.35 | 14.66 | -0.24 | -7.33 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.34 |
| Total Debt / Equity (X) | 0.00 | 0.16 | 0.17 | 0.00 | 0.34 |
| Asset Turnover Ratio (%) | 0.19 | 0.03 | 0.66 | 0.01 | 0.02 |
| Current Ratio (X) | 5.73 | 3.68 | 2.88 | 5.31 | 0.18 |
| Quick Ratio (X) | 5.10 | 3.68 | 2.88 | 5.31 | 0.18 |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
| Interest Coverage Ratio (X) | 0.00 | 0.00 | 0.00 | -6.89 | -0.76 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | 0.00 | 0.00 | -9.05 | -2.15 |
| Enterprise Value (Cr.) | 17.85 | 11.20 | 7.21 | 7.56 | 8.74 |
| EV / Net Operating Revenue (X) | 21.15 | 67.84 | 2.65 | 107.10 | 42.02 |
| EV / EBITDA (X) | 40.21 | 689.51 | 7.83 | -25.72 | -64.70 |
| MarketCap / Net Operating Revenue (X) | 21.21 | 64.23 | 2.44 | 107.14 | 34.64 |
| Price / BV (X) | 4.59 | 2.99 | 1.88 | 2.63 | 1.61 |
| Price / Net Operating Revenue (X) | 21.21 | 64.28 | 2.44 | 107.14 | 34.65 |
| EarningsYield | 0.01 | 0.00 | 0.09 | 0.00 | -0.07 |
After reviewing the key financial ratios for Genomic Valley Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 5. It has increased from 0.05 (Mar 24) to 1.17, marking an increase of 1.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 5. It has increased from 0.05 (Mar 24) to 1.17, marking an increase of 1.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 3. It has increased from 0.05 (Mar 24) to 1.17, marking an increase of 1.12.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 12.76. It has increased from 11.60 (Mar 24) to 12.76, marking an increase of 1.16.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 12.76. It has increased from 11.60 (Mar 24) to 12.76, marking an increase of 1.16.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 2.76. It has increased from 0.54 (Mar 24) to 2.76, marking an increase of 2.22.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 2. It has increased from 0.05 (Mar 24) to 1.45, marking an increase of 1.40.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 0.04 (Mar 24) to 1.45, marking an increase of 1.41.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 0.04 (Mar 24) to 1.45, marking an increase of 1.41.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.17. This value is below the healthy minimum of 2. It has increased from 0.04 (Mar 24) to 1.17, marking an increase of 1.13.
- For PBDIT Margin (%), as of Mar 25, the value is 52.60. This value is within the healthy range. It has increased from 9.83 (Mar 24) to 52.60, marking an increase of 42.77.
- For PBIT Margin (%), as of Mar 25, the value is 52.30. This value exceeds the healthy maximum of 20. It has increased from 9.17 (Mar 24) to 52.30, marking an increase of 43.13.
- For PBT Margin (%), as of Mar 25, the value is 52.30. This value is within the healthy range. It has increased from 9.17 (Mar 24) to 52.30, marking an increase of 43.13.
- For Net Profit Margin (%), as of Mar 25, the value is 42.19. This value exceeds the healthy maximum of 10. It has increased from 9.19 (Mar 24) to 42.19, marking an increase of 33.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is 9.13. This value is below the healthy minimum of 15. It has increased from 0.42 (Mar 24) to 9.13, marking an increase of 8.71.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.32. This value is within the healthy range. It has increased from 0.42 (Mar 24) to 11.32, marking an increase of 10.90.
- For Return On Assets (%), as of Mar 25, the value is 8.17. This value is within the healthy range. It has increased from 0.35 (Mar 24) to 8.17, marking an increase of 7.82.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.16 (Mar 24) to 0.00, marking a decrease of 0.16.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.19. It has increased from 0.03 (Mar 24) to 0.19, marking an increase of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 5.73. This value exceeds the healthy maximum of 3. It has increased from 3.68 (Mar 24) to 5.73, marking an increase of 2.05.
- For Quick Ratio (X), as of Mar 25, the value is 5.10. This value exceeds the healthy maximum of 2. It has increased from 3.68 (Mar 24) to 5.10, marking an increase of 1.42.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 17.85. It has increased from 11.20 (Mar 24) to 17.85, marking an increase of 6.65.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 21.15. This value exceeds the healthy maximum of 3. It has decreased from 67.84 (Mar 24) to 21.15, marking a decrease of 46.69.
- For EV / EBITDA (X), as of Mar 25, the value is 40.21. This value exceeds the healthy maximum of 15. It has decreased from 689.51 (Mar 24) to 40.21, marking a decrease of 649.30.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 21.21. This value exceeds the healthy maximum of 3. It has decreased from 64.23 (Mar 24) to 21.21, marking a decrease of 43.02.
- For Price / BV (X), as of Mar 25, the value is 4.59. This value exceeds the healthy maximum of 3. It has increased from 2.99 (Mar 24) to 4.59, marking an increase of 1.60.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 21.21. This value exceeds the healthy maximum of 3. It has decreased from 64.28 (Mar 24) to 21.21, marking a decrease of 43.07.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genomic Valley Biotech Ltd:
- Net Profit Margin: 42.19%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.32% (Industry Average ROCE: 16.97%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 9.13% (Industry Average ROE: 15.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.1
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 75.5 (Industry average Stock P/E: 34.41)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 42.19%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Seeds/Tissue Culture/Bio Technology | 4KM Stone, Berry Charra Road, P.O. Tanda Hari, Jhajjar District Haryana 124507 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Yogesh Agrawal | Managing Director |
| Mrs. Parul Agrawal | Non Executive Director |
| Mr. Ashok Kumar | Non Executive Director |
| Mr. Satendra Kumar Goyal | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd's intrinsic value (as of 30 December 2025) is 76.41 which is 209.35% higher the current market price of 24.70, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 7.55 Cr. market cap, FY2025-2026 high/low of 94.0/21.0, reserves of ₹0.87 Cr, and liabilities of 4.33 Cr.
What is the Market Cap of Genomic Valley Biotech Ltd?
The Market Cap of Genomic Valley Biotech Ltd is 7.55 Cr..
What is the current Stock Price of Genomic Valley Biotech Ltd as on 30 December 2025?
The current stock price of Genomic Valley Biotech Ltd as on 30 December 2025 is 24.7.
What is the High / Low of Genomic Valley Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Genomic Valley Biotech Ltd stocks is 94.0/21.0.
What is the Stock P/E of Genomic Valley Biotech Ltd?
The Stock P/E of Genomic Valley Biotech Ltd is 75.5.
What is the Book Value of Genomic Valley Biotech Ltd?
The Book Value of Genomic Valley Biotech Ltd is 12.8.
What is the Dividend Yield of Genomic Valley Biotech Ltd?
The Dividend Yield of Genomic Valley Biotech Ltd is 0.00 %.
What is the ROCE of Genomic Valley Biotech Ltd?
The ROCE of Genomic Valley Biotech Ltd is 11.8 %.
What is the ROE of Genomic Valley Biotech Ltd?
The ROE of Genomic Valley Biotech Ltd is 9.69 %.
What is the Face Value of Genomic Valley Biotech Ltd?
The Face Value of Genomic Valley Biotech Ltd is 10.0.